Advertisement

Reply to “GLP1RA versus SGLT2i tended to have more favorable ischemic outcomes including stroke?”

  • In-Chang Hwang
    Correspondence
    Corresponding author at: Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, South Korea.
    Affiliations
    Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, South Korea
    Search for articles by this author
  • Chee Hae Kim
    Affiliations
    Division of Cardiology, Department of Internal Medicine, VHS Medical Center, Seoul, South Korea
    Search for articles by this author
      We appreciated Du et al.'s valuable comments on our recent study. [
      • Du L.
      • Zhang Y.
      • Wang P.
      • Li Z.
      • Zhao Y.
      • Yuan J.
      GLP1RA Versus SGLT2i Tended to have more Favorable Ischemic Outcomes Including Stroke?.
      ] As described by the author, the reduced trend of a composite ischemic outcome in the glucagon-like peptide-1 receptor agonists (GLP1RA) group, compared to the sodium-glucose cotransporter 2 inhibitors (SGLT2i) group, was mainly derived by acute coronary syndrome (ACS). However, despite the lack of statistical significance due to the low event rates, it was noted that the annualized rates (per 100 person-year) for each component of ischemic events were lower in the GLP1RA group than SGLT2i group: ACS 0.25 vs. 0.92; coronary revascularization 0.51 vs. 0.69; and stroke 0.25 vs. 0.45, respectively.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Du L.
        • Zhang Y.
        • Wang P.
        • Li Z.
        • Zhao Y.
        • Yuan J.
        GLP1RA Versus SGLT2i Tended to have more Favorable Ischemic Outcomes Including Stroke?.
        (LID - S0167–5273(22)01040–3 [pii] LID - 10.1016/j.ijcard.2022.07.015 [doi] FAU - Du, Lixin. (1874–1754 (Electronic)))2022
        • Imprialos K.P.
        • Boutari C.
        • Stavropoulos K.
        • Doumas M.
        • Karagiannis A.I.
        Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?.
        J. Neurol. Neurosurg. Psychiatry. 2017; 88: 249-253
        • Strain W.D.
        • Frenkel O.
        • James M.A.
        • Leiter L.A.
        • Rasmussen S.
        • Rothwell P.M.
        • et al.
        Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6.
        Stroke. 2022; 53: 2749-2757
        • Goldenberg R.M.
        • Cheng A.Y.Y.
        • Fitzpatrick T.
        • Gilbert J.D.
        • Verma S.
        • Hopyan J.J.
        Benefits of GLP-1 (glucagon-like peptide 1) receptor agonists for stroke reduction in type 2 diabetes: a call to action for neurologists.
        Stroke. 2022; 53: 1813-1822
        • Htoo P.T.
        • Buse J.
        • Cavender M.
        • Wang T.
        • Pate V.
        • Edwards J.
        • et al.
        Cardiovascular effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like Peptide-1 receptor agonists in older patients in routine clinical care with or without history of atherosclerotic cardiovascular diseases or heart failure.
        J. Am. Heart Assoc. 2022; 11e022376